News
3monon MSN
a first-in-class HIF-2α inhibitor. The findings are published in The Lancet Oncology journal. The researchers previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback